Cargando…

The First Occurrence of Angioedema After Discontinuation of Angiotensin-Converting Enzyme Inhibitor

Angioedema is one of the dreaded side effects of angiotensin-converting enzyme (ACE) inhibitors. It has been well established in the literature and the timing of onset is variable from months to years after initiation of therapy. Patients remain at risk of recurrence of angioedema even after discont...

Descripción completa

Detalles Bibliográficos
Autores principales: Kainat, Aleesha, Phang, Chen Rong, Ain, Noor Ul, Agarwal, Bhawna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669203/
https://www.ncbi.nlm.nih.gov/pubmed/34917435
http://dx.doi.org/10.7759/cureus.19553
_version_ 1784614733208354816
author Kainat, Aleesha
Phang, Chen Rong
Ain, Noor Ul
Agarwal, Bhawna
author_facet Kainat, Aleesha
Phang, Chen Rong
Ain, Noor Ul
Agarwal, Bhawna
author_sort Kainat, Aleesha
collection PubMed
description Angioedema is one of the dreaded side effects of angiotensin-converting enzyme (ACE) inhibitors. It has been well established in the literature and the timing of onset is variable from months to years after initiation of therapy. Patients remain at risk of recurrence of angioedema even after discontinuation of the drug if they developed it once while on the drug. While only recurrences of ACE inhibitor-induced angioedema are described in the literature, our patient did not develop angioedema while being on the drug and had the first occurrence of angioedema one month after the medication was discontinued. We argue that since our patient did report an ACE inhibitor-related dry cough, this case emphasizes the strength of the relation between the two common side effects of the ACE inhibitors. This favors that among the risk factors that predispose individuals to develop angioedema, ACE inhibitor-associated cough is a major one. Although the mechanism of ACE inhibitor-related cough is poorly understood, bradykinin seems to be the common culprit mediator for these two side effects. Hence, clinicians need to be aware of this potential threat and be cautioned when they witness an ACE inhibitor-related cough.
format Online
Article
Text
id pubmed-8669203
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-86692032021-12-15 The First Occurrence of Angioedema After Discontinuation of Angiotensin-Converting Enzyme Inhibitor Kainat, Aleesha Phang, Chen Rong Ain, Noor Ul Agarwal, Bhawna Cureus Internal Medicine Angioedema is one of the dreaded side effects of angiotensin-converting enzyme (ACE) inhibitors. It has been well established in the literature and the timing of onset is variable from months to years after initiation of therapy. Patients remain at risk of recurrence of angioedema even after discontinuation of the drug if they developed it once while on the drug. While only recurrences of ACE inhibitor-induced angioedema are described in the literature, our patient did not develop angioedema while being on the drug and had the first occurrence of angioedema one month after the medication was discontinued. We argue that since our patient did report an ACE inhibitor-related dry cough, this case emphasizes the strength of the relation between the two common side effects of the ACE inhibitors. This favors that among the risk factors that predispose individuals to develop angioedema, ACE inhibitor-associated cough is a major one. Although the mechanism of ACE inhibitor-related cough is poorly understood, bradykinin seems to be the common culprit mediator for these two side effects. Hence, clinicians need to be aware of this potential threat and be cautioned when they witness an ACE inhibitor-related cough. Cureus 2021-11-13 /pmc/articles/PMC8669203/ /pubmed/34917435 http://dx.doi.org/10.7759/cureus.19553 Text en Copyright © 2021, Kainat et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Kainat, Aleesha
Phang, Chen Rong
Ain, Noor Ul
Agarwal, Bhawna
The First Occurrence of Angioedema After Discontinuation of Angiotensin-Converting Enzyme Inhibitor
title The First Occurrence of Angioedema After Discontinuation of Angiotensin-Converting Enzyme Inhibitor
title_full The First Occurrence of Angioedema After Discontinuation of Angiotensin-Converting Enzyme Inhibitor
title_fullStr The First Occurrence of Angioedema After Discontinuation of Angiotensin-Converting Enzyme Inhibitor
title_full_unstemmed The First Occurrence of Angioedema After Discontinuation of Angiotensin-Converting Enzyme Inhibitor
title_short The First Occurrence of Angioedema After Discontinuation of Angiotensin-Converting Enzyme Inhibitor
title_sort first occurrence of angioedema after discontinuation of angiotensin-converting enzyme inhibitor
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669203/
https://www.ncbi.nlm.nih.gov/pubmed/34917435
http://dx.doi.org/10.7759/cureus.19553
work_keys_str_mv AT kainataleesha thefirstoccurrenceofangioedemaafterdiscontinuationofangiotensinconvertingenzymeinhibitor
AT phangchenrong thefirstoccurrenceofangioedemaafterdiscontinuationofangiotensinconvertingenzymeinhibitor
AT ainnoorul thefirstoccurrenceofangioedemaafterdiscontinuationofangiotensinconvertingenzymeinhibitor
AT agarwalbhawna thefirstoccurrenceofangioedemaafterdiscontinuationofangiotensinconvertingenzymeinhibitor
AT kainataleesha firstoccurrenceofangioedemaafterdiscontinuationofangiotensinconvertingenzymeinhibitor
AT phangchenrong firstoccurrenceofangioedemaafterdiscontinuationofangiotensinconvertingenzymeinhibitor
AT ainnoorul firstoccurrenceofangioedemaafterdiscontinuationofangiotensinconvertingenzymeinhibitor
AT agarwalbhawna firstoccurrenceofangioedemaafterdiscontinuationofangiotensinconvertingenzymeinhibitor